Derik De Bruin
Stock Analyst at B of A Securities
(4.96)
# 26
Out of 4,898 analysts
217
Total ratings
66.44%
Success rate
84.52%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Buy | $116 → $110 | $98.47 | +11.71% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $43.21 | +15.71% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $12.47 | +4.25% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $48.28 | +9.78% | 6 | Jun 26, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,200 → $1,260 | $1,193.89 | +5.54% | 10 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $304.18 | +23.28% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $120.08 | +6.60% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.21 | +111.13% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $54.30 | +19.71% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $7.18 | +122.84% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $425.34 | +55.17% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $160.13 | +46.76% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $158.04 | +32.88% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $224.49 | +58.14% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $25.65 | +1.36% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $249.80 | +8.49% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $168.37 | +8.10% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $197.75 | +46.65% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $31.54 | -52.44% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $5.01 | +319.16% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $21.14 | +51.37% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $98.53 | +1.49% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $64.62 | +33.09% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.12 | +215.53% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.14 | +204.45% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $149.66 | +73.73% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.94 | +1,107.24% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $155.65 | -22.90% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.68 | +435.71% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $531.42 | -55.78% | 3 | Nov 2, 2018 |
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $98.47
Upside: +11.71%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $43.21
Upside: +15.71%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $12.47
Upside: +4.25%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $48.28
Upside: +9.78%
Mettler-Toledo International
Jun 26, 2025
Maintains: Neutral
Price Target: $1,200 → $1,260
Current: $1,193.89
Upside: +5.54%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $304.18
Upside: +23.28%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $120.08
Upside: +6.60%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.21
Upside: +111.13%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $54.30
Upside: +19.71%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.18
Upside: +122.84%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $425.34
Upside: +55.17%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $160.13
Upside: +46.76%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $158.04
Upside: +32.88%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $224.49
Upside: +58.14%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $25.65
Upside: +1.36%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $249.80
Upside: +8.49%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $168.37
Upside: +8.10%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $197.75
Upside: +46.65%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $31.54
Upside: -52.44%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $5.01
Upside: +319.16%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $21.14
Upside: +51.37%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $98.53
Upside: +1.49%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $64.62
Upside: +33.09%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.12
Upside: +215.53%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.14
Upside: +204.45%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $149.66
Upside: +73.73%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.94
Upside: +1,107.24%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $155.65
Upside: -22.90%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.68
Upside: +435.71%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $531.42
Upside: -55.78%